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Underutilization of Oral Anticoagulant Therapy in At-Risk Patients with Atrial 
Fibrillation—Insights from a Multistate Health Care System
Ty J. Gluckman, MD1, Amir Ali2, Callie Scott2, John L. Petersen II, MD3
Background
• Oral anticoagulant (OAC) therapy significantly reduces the risk of thromboembolism 
among at-risk patients with atrial fibrillation (AF)1,2.
• Current guidelines provide strong support for use of OAC therapy in men and women 
with AF and CHA2DS2-VASc scores of >2 and >3, respectively
3.
• Previous national registry data has suggested that as many as 40% of these patients 
are not treated in accordance with guideline recommendations4.
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Methods
• Cross-sectional analysis (August 1, 2018) of patients with AF from a multistate health 
care system.
• Electronic health record and coding (ICD-10) data was used to identify patients with 
AF, calculate their CHA2DS2-VASc score, and define their current antithrombotic 
regimen.
• Men with a CHA2DS2-VASc score <2 and women with a CHA2DS2-VASc score <3 
were excluded from the analysis.
• Individuals on both OAC and antiplatelet therapy were classified as receiving OAC 
therapy.
• Demographics and comorbidities for 102,728 unique patients with AF were assessed 
to allow for comparison between those receiving an OAC from those who were not.
• Categorical variables were expressed as counts with percentages. Proportions of 
categorical variables were compared between groups by chi-square test or Fisher 
exact test, as appropriate. All significance tests were two tailed and a p value less than 
0.05 was considered statistically significant. Tukey method was used for post-hoc 
multiple comparisons testing when needed. 
• SAS version 9.4 (SAS Institute Inc.) was used for all analyses.
Conclusions
• In a contemporary, non-registry setting, OAC underuse remains substantial among at-
risk patients with AF.
• Further investigation into tools that facilitate implementation of guideline-directed 
medical therapy is needed to limit preventable thromboembolic events in this 
population.
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Table 1 – Demographics. Counts with percentages of patients with AF overall, on OAC 
therapy, on APT therapy, or on no antithrombotic therapy with corresponding p values.
Objective
• Using real-world data from a large multistate health care system, we sought to 
evaluate the prevalence of OAC underuse and potential contributing factors in an 
ambulatory population of at-risk patients with AF.
• Among AF patients appropriate for OAC therapy based on their CHA2DS2-VASc score, 
antiplatelet therapy was more likely to be used in those with coronary artery disease 
(27.5% vs. 21.5%, p=0.0001), prior myocardial infarction (6.1% vs. 3.1%, p=0.0001), 
peripheral vascular disease (8.4% vs. 6.4%, p=0.0001) and renal disease (21.7% vs. 
18.4%, p=0.0001).
• Among AF patients appropriate for OAC therapy based on their CHA2DS2-VASc score, 
no antihrombotic therapy was more likely to be used in women (52.1% vs. 46.9%, 
p=0.0001) and those with renal disease (21.3% vs. 18.4%, p=0.0001) and liver disease 
(2.5% vs. 1.6%, p=0.0001).
AF = atrial fibrillation, APT = antiplatelet, DOAC = direct-acting oral anticoagulant, OAC = oral anticoagulant, P2Y12i = P2Y12 inhibitor, VKA = vitamin K antagonist
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Gender                  
(n, % male)






7391   
(47.9)
0.43 0.0001 0.0001
Race (n, %) 0.0003 0.0001 0.0939
American Indian 
or Alaska Native
635          
(0.6)
378       
(0.6)
170       
(0.7)
87          
(0.6)
Asian
3171      
(3.2)
1811     
(3.0)
845       
(3.4)
515       
(3.4)
Black or African 
American
1671      
(1.7)
933       
(1.5)
440       
(1.8)
298       
(2.0)
Native Hawaiian 
or Other Pacific 
Islander
332        
(0.3)
199       
(0.3)
74         
(0.3)
59          
(0.4)
Other
4030      
(4.0)
2337      
(3.9)
1020    
(4.1)












Ethnicity               
(n, % Hispanic)
3144      
(3.1)
1826         
(3.0)
793       
(3.2)
525        
(3.5)
0.13 0.0021 0.1181
Insurance 0.0205 0.001 0.0779
Commercial
5569      
(5.5)
3500     
(5.7)
1290    
(5.2)
779       
(5.2)
Medicaid
1405      
(1.4)
812       
(1.3)
348        
(1.4)












3605      
(3.6)
2197     
(3.6)
912       
(3.7)
496       
(3.3)








8595   
(55.8)
0.1273 0.0001 0.0001
























3940      
(3.8)
1904     
(3.1)
1549    
(6.1)
487       
(3.2)
0.0001 0.57 0.0001














7021      
(6.8)
3977     
(6.4)
2126    
(8.4)
918       
(6.0)
0.0001 0.0365 0.0001
Heart failure        
(n, %)




4576   
(18.1)
2658   
(17.2)
0.4531 0.0021 0.0301








3289   
(21.3)
0.0001 0.0001 0.46
Liver disease       
(n, %)
1897      
(1.9)
992       
(1.6)
519       
(2.1)
386       
(2.5)
0.0001 0.0001 0.0027
Figure 2 – Distribution of antithrombotic treatments. Men and women with AF and a 

















VKA + DOAC VKA + Aspirin
VKA + P2Y12i DOAC + Aspirin
DOAC + P2Y12i Aspirin + P2Y12i
VKA + DOAC + Aspirin VKA + Aspirin + P2Y12i
DOAC + Aspirin + P2Y12i No antithrombotic therapy
